

# **Marine Derived Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Ether, Peptide, Phenol, Steroid), By Source (Algae, Invertebrates, Microorganisms), By Application (Anti-Cardiovascular, Anti-Inflammatory, Anti-Microbial, Anti-Tumor, Anti-Viral), By Region & Competition, 2021-2031F**

<https://marketpublishers.com/r/MD4079F99410EN.html>

Date: May 2026

Pages: 177

Price: US\$ 4,500.00 (Single User License)

ID: MD4079F99410EN

## **Abstracts**

The Global Marine Derived Drugs Market is projected to expand significantly, from USD 13.02 billion in 2025 to USD 21.99 billion by 2031, demonstrating a compound annual growth rate of 9.13%. This market involves therapeutically valuable compounds extracted from marine organisms like sponges, algae, and mollusks, used to treat various human diseases. Key growth drivers include the increasing global incidence of chronic conditions such as cancer and cardiovascular diseases, coupled with a pressing need for new antibiotics to tackle drug-resistant infections.

Furthermore, advances in deep-sea bioprospecting technologies are opening up access to previously inaccessible marine biodiversity, thereby enriching the pool of potential pharmaceutical candidates. However, the market confronts considerable challenges in terms of scalability and resource sustainability. With only about 15 to 20 approved marine-derived compounds globally for human use in 2024, according to the Royal Pharmaceutical Society, a major barrier to rapid expansion is the difficulty of securing a sustainable supply. Harvesting adequate quantities from wild marine sources is often ecologically harmful and economically impractical, while chemically synthesizing these complex molecules remains technically challenging.

## **Market Driver**

The increasing incidence of cancer and other chronic diseases is a principal driver for the Global Marine Derived Drugs Market, creating an urgent need for innovative therapeutics with distinct mechanisms of action. Marine organisms, particularly sponges and tunicates, are sources of powerful bioactive compounds like cytostatics and antibody-drug conjugates, crucial for addressing resistant cancers. This demand is evidenced by the substantial commercial success of approved marine therapeutics, such as Adcetris, which generated \$1,089 million in sales in 2024, and Zepzelca, whose net sales rose by 11% to \$320.3 million in 2024 for small cell lung cancer, according to Pfizer and Jazz Pharmaceuticals respectively.

Concurrently, significant government funding and breakthroughs in deep-sea bioprospecting technologies are overcoming previous hurdles related to sustainable supply and high exploration expenses. Public sector investments are mitigating the risks associated with early-stage marine biodiversity discovery, allowing private pharmaceutical companies to prioritize clinical development. For example, the National Oceanic and Atmospheric Administration allocated \$16.7 million in June 2024 to support marine technology innovation, which directly bolsters the industry's capability to identify and sustainably source pharmacological candidates from previously unreachable ocean environments, ensuring a continuous supply for future drug development.

### **Market Challenge**

A significant obstacle for the Global Marine Derived Drugs Market is the challenge of establishing a sustainable and scalable supply chain. Marine organisms contain powerful bioactive compounds, but their low natural concentrations often demand large harvest volumes that are both ecologically unsustainable and economically inefficient. Alternatively, the chemical synthesis of these complex molecules frequently encounters substantial technical difficulties and high production costs. This leads to a critical supply gap, as pharmaceutical developers struggle to produce commercial quantities of drug candidates, sometimes leading to the discontinuation of promising therapies in late-stage trials due to unreliable active pharmaceutical ingredient sources.

This manufacturing limitation directly hinders market capitalization and commercial expansion, keeping the sector niche despite its extensive biological potential because companies cannot easily transition from laboratory discovery to industrial-scale production. The economic ramifications of this scalability issue are evident in the industry's modest financial presence. The European Commission's 2025 Blue Economy Report, for instance, noted that the blue biotechnology sector in the European Union

generated only approximately €942 million in turnover, highlighting the considerable difficulties the industry faces in achieving the mass-market volumes necessary to rival terrestrial pharmaceutical segments.

## **Market Trends**

A significant trend is the diversification of clinical pipelines beyond oncology into areas such as neurodegenerative and infectious diseases, thereby broadening the market's scope and lessening its traditional dependence on cancer treatments. Developers are increasingly utilizing the distinct chemical structures of marine-derived compounds to target new pathways, including those for ophthalmology and RNA interference therapies. This strategic expansion is bolstered by considerable public-private investments aimed at reducing the risks associated with these non-oncological indications. For example, PharmaMar's subsidiary Sylentis received a €21.1 million grant from the European Commission in October 2025 to advance its RNAi-based clinical pipeline, indicating a rising commitment to applying marine biotechnology across a broader spectrum of human pathologies.

Concurrently, the formation of collaborative academic-industry consortia for clinical translation is emerging as the primary operational model for commercializing marine discoveries. Due to the high costs and technical complexities inherent in marine drug development, specialized biotech firms are forming licensing agreements with large pharmaceutical companies to manage late-stage clinical trials and global distribution. This synergistic approach enables discovery-focused entities to concentrate on research, while their partners handle the commercial infrastructure. Jazz Pharmaceuticals' report of \$79.3 million in net product sales for the marine-derived therapeutic Zepzelca in November 2025 further validates the financial viability of this partnership model in bringing complex marine agents to the global market.

## **Key Market Players**

Abbott Laboratories Inc

Bayer AG

Takeda Pharmaceutical Co Ltd

Marine Polymer Technologies Inc

Sanofi SA

Aphios Corp

Aker BioMarine ASA

AbbVie Inc

GSK PLC

## Report Scope

In this report, the Global Marine Derived Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

### Marine Derived Drugs Market, By Type

Ether

Peptide

Phenol

Steroid

### Marine Derived Drugs Market, By Source

Algae

Invertebrates

Microorganisms

### Marine Derived Drugs Market, By Application

Anti-Cardiovascular

Anti-Inflammatory

Anti-Microbial

Anti-Tumor

Anti-Viral

## Marine Derived Drugs Market, By Region

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

### **Competitive Landscape**

Company Profiles: Detailed analysis of the major companies present in the Global Marine Derived Drugs Market.

### **Available Customizations:**

Global Marine Derived Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

### **Company Information**

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. GLOBAL MARINE DERIVED DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Type (Ether, Peptide, Phenol, Steroid)
  - 5.2.2. By Source (Algae, Invertebrates, Microorganisms)
  - 5.2.3. By Application (Anti-Cardiovascular, Anti-Inflammatory, Anti-Microbial, Anti-Tumor, Anti-Viral)

- 5.2.4. By Region
- 5.2.5. By Company (2025)
- 5.3. Market Map

## **6. NORTH AMERICA MARINE DERIVED DRUGS MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Type
  - 6.2.2. By Source
  - 6.2.3. By Application
  - 6.2.4. By Country
- 6.3. North America: Country Analysis
  - 6.3.1. United States Marine Derived Drugs Market Outlook
    - 6.3.1.1. Market Size & Forecast
      - 6.3.1.1.1. By Value
    - 6.3.1.2. Market Share & Forecast
      - 6.3.1.2.1. By Type
      - 6.3.1.2.2. By Source
      - 6.3.1.2.3. By Application
  - 6.3.2. Canada Marine Derived Drugs Market Outlook
    - 6.3.2.1. Market Size & Forecast
      - 6.3.2.1.1. By Value
    - 6.3.2.2. Market Share & Forecast
      - 6.3.2.2.1. By Type
      - 6.3.2.2.2. By Source
      - 6.3.2.2.3. By Application
  - 6.3.3. Mexico Marine Derived Drugs Market Outlook
    - 6.3.3.1. Market Size & Forecast
      - 6.3.3.1.1. By Value
    - 6.3.3.2. Market Share & Forecast
      - 6.3.3.2.1. By Type
      - 6.3.3.2.2. By Source
      - 6.3.3.2.3. By Application

## **7. EUROPE MARINE DERIVED DRUGS MARKET OUTLOOK**

- 7.1. Market Size & Forecast

- 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Type
  - 7.2.2. By Source
  - 7.2.3. By Application
  - 7.2.4. By Country
- 7.3. Europe: Country Analysis
  - 7.3.1. Germany Marine Derived Drugs Market Outlook
    - 7.3.1.1. Market Size & Forecast
      - 7.3.1.1.1. By Value
    - 7.3.1.2. Market Share & Forecast
      - 7.3.1.2.1. By Type
      - 7.3.1.2.2. By Source
      - 7.3.1.2.3. By Application
  - 7.3.2. France Marine Derived Drugs Market Outlook
    - 7.3.2.1. Market Size & Forecast
      - 7.3.2.1.1. By Value
    - 7.3.2.2. Market Share & Forecast
      - 7.3.2.2.1. By Type
      - 7.3.2.2.2. By Source
      - 7.3.2.2.3. By Application
  - 7.3.3. United Kingdom Marine Derived Drugs Market Outlook
    - 7.3.3.1. Market Size & Forecast
      - 7.3.3.1.1. By Value
    - 7.3.3.2. Market Share & Forecast
      - 7.3.3.2.1. By Type
      - 7.3.3.2.2. By Source
      - 7.3.3.2.3. By Application
  - 7.3.4. Italy Marine Derived Drugs Market Outlook
    - 7.3.4.1. Market Size & Forecast
      - 7.3.4.1.1. By Value
    - 7.3.4.2. Market Share & Forecast
      - 7.3.4.2.1. By Type
      - 7.3.4.2.2. By Source
      - 7.3.4.2.3. By Application
  - 7.3.5. Spain Marine Derived Drugs Market Outlook
    - 7.3.5.1. Market Size & Forecast
      - 7.3.5.1.1. By Value
    - 7.3.5.2. Market Share & Forecast

- 7.3.5.2.1. By Type
- 7.3.5.2.2. By Source
- 7.3.5.2.3. By Application

## **8. ASIA PACIFIC MARINE DERIVED DRUGS MARKET OUTLOOK**

- 8.1. Market Size & Forecast
  - 8.1.1. By Value
- 8.2. Market Share & Forecast
  - 8.2.1. By Type
  - 8.2.2. By Source
  - 8.2.3. By Application
  - 8.2.4. By Country
- 8.3. Asia Pacific: Country Analysis
  - 8.3.1. China Marine Derived Drugs Market Outlook
    - 8.3.1.1. Market Size & Forecast
      - 8.3.1.1.1. By Value
    - 8.3.1.2. Market Share & Forecast
      - 8.3.1.2.1. By Type
      - 8.3.1.2.2. By Source
      - 8.3.1.2.3. By Application
  - 8.3.2. India Marine Derived Drugs Market Outlook
    - 8.3.2.1. Market Size & Forecast
      - 8.3.2.1.1. By Value
    - 8.3.2.2. Market Share & Forecast
      - 8.3.2.2.1. By Type
      - 8.3.2.2.2. By Source
      - 8.3.2.2.3. By Application
  - 8.3.3. Japan Marine Derived Drugs Market Outlook
    - 8.3.3.1. Market Size & Forecast
      - 8.3.3.1.1. By Value
    - 8.3.3.2. Market Share & Forecast
      - 8.3.3.2.1. By Type
      - 8.3.3.2.2. By Source
      - 8.3.3.2.3. By Application
  - 8.3.4. South Korea Marine Derived Drugs Market Outlook
    - 8.3.4.1. Market Size & Forecast
      - 8.3.4.1.1. By Value
    - 8.3.4.2. Market Share & Forecast

- 8.3.4.2.1. By Type
- 8.3.4.2.2. By Source
- 8.3.4.2.3. By Application
- 8.3.5. Australia Marine Derived Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Source
    - 8.3.5.2.3. By Application

## **9. MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET OUTLOOK**

- 9.1. Market Size & Forecast
  - 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Type
  - 9.2.2. By Source
  - 9.2.3. By Application
  - 9.2.4. By Country
- 9.3. Middle East & Africa: Country Analysis
  - 9.3.1. Saudi Arabia Marine Derived Drugs Market Outlook
    - 9.3.1.1. Market Size & Forecast
      - 9.3.1.1.1. By Value
    - 9.3.1.2. Market Share & Forecast
      - 9.3.1.2.1. By Type
      - 9.3.1.2.2. By Source
      - 9.3.1.2.3. By Application
  - 9.3.2. UAE Marine Derived Drugs Market Outlook
    - 9.3.2.1. Market Size & Forecast
      - 9.3.2.1.1. By Value
    - 9.3.2.2. Market Share & Forecast
      - 9.3.2.2.1. By Type
      - 9.3.2.2.2. By Source
      - 9.3.2.2.3. By Application
  - 9.3.3. South Africa Marine Derived Drugs Market Outlook
    - 9.3.3.1. Market Size & Forecast
      - 9.3.3.1.1. By Value
    - 9.3.3.2. Market Share & Forecast

- 9.3.3.2.1. By Type
- 9.3.3.2.2. By Source
- 9.3.3.2.3. By Application

## **10. SOUTH AMERICA MARINE DERIVED DRUGS MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Type
  - 10.2.2. By Source
  - 10.2.3. By Application
  - 10.2.4. By Country
- 10.3. South America: Country Analysis
  - 10.3.1. Brazil Marine Derived Drugs Market Outlook
    - 10.3.1.1. Market Size & Forecast
      - 10.3.1.1.1. By Value
    - 10.3.1.2. Market Share & Forecast
      - 10.3.1.2.1. By Type
      - 10.3.1.2.2. By Source
      - 10.3.1.2.3. By Application
  - 10.3.2. Colombia Marine Derived Drugs Market Outlook
    - 10.3.2.1. Market Size & Forecast
      - 10.3.2.1.1. By Value
    - 10.3.2.2. Market Share & Forecast
      - 10.3.2.2.1. By Type
      - 10.3.2.2.2. By Source
      - 10.3.2.2.3. By Application
  - 10.3.3. Argentina Marine Derived Drugs Market Outlook
    - 10.3.3.1. Market Size & Forecast
      - 10.3.3.1.1. By Value
    - 10.3.3.2. Market Share & Forecast
      - 10.3.3.2.1. By Type
      - 10.3.3.2.2. By Source
      - 10.3.3.2.3. By Application

## **11. MARKET DYNAMICS**

- 11.1. Drivers

## 11.2. Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

### 12.1. Merger & Acquisition (If Any)

### 12.2. Product Launches (If Any)

### 12.3. Recent Developments

## **13. GLOBAL MARINE DERIVED DRUGS MARKET: SWOT ANALYSIS**

## **14. PORTER'S FIVE FORCES ANALYSIS**

### 14.1. Competition in the Industry

### 14.2. Potential of New Entrants

### 14.3. Power of Suppliers

### 14.4. Power of Customers

### 14.5. Threat of Substitute Products

## **15. COMPETITIVE LANDSCAPE**

### 15.1. Abbott Laboratories Inc

#### 15.1.1. Business Overview

#### 15.1.2. Products & Services

#### 15.1.3. Recent Developments

#### 15.1.4. Key Personnel

#### 15.1.5. SWOT Analysis

### 15.2. Bayer AG

### 15.3. Takeda Pharmaceutical Co Ltd

### 15.4. Marine Polymer Technologies Inc

### 15.5. Sanofi SA

### 15.6. Aphios Corp

### 15.7. Aker BioMarine ASA

### 15.8. AbbVie Inc

### 15.9. GSK PLC

## **16. STRATEGIC RECOMMENDATIONS**

## **17. ABOUT US & DISCLAIMER**

## I would like to order

Product name: Marine Derived Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Ether, Peptide, Phenol, Steroid), By Source (Algae, Invertebrates, Microorganisms), By Application (Anti-Cardiovascular, Anti-Inflammatory, Anti-Microbial, Anti-Tumor, Anti-Viral), By Region & Competition, 2021-2031F

Product link: <https://marketpublishers.com/r/MD4079F99410EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MD4079F99410EN.html>